Isovanillin-derived bis-hydrazones as dual cholinesterase and carbonic anhydrase inhibitors: synthesis, enzymatic profiling, and computational insights from molecular docking and dynamics
Özet
Aims: To develop isovanillin-based bis-hydrazones as multitarget inhibitors of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and human carbonic anhydrase I/II (hCA I/II). Materials & methods: Twelve bis-hydrazones (4a–4l) were synthesized in two steps and evaluated by spectrophotometric enzyme assays, Lineweaver–Burk kinetics, molecular docking, MM-GBSA, molecular dynamics simulations, and in silico ADME/Tox profiling. Results: All compounds showed nanomolar inhibition. Compound 4d was the most potent AChE/BChE inhibitor (KI = 10.46 and 3.56 nM), while 4a and 4j led the hCA I/II panel (KI = 3.46 and 16.12 nM). Docking, MM-GBSA, and molecular dynamics supported dual-site cholinesterase engagement and non-zinc, peripherally anchored hCA inhibition. Conclusions: Isovanillin-based bis-hydrazones, particularly 4d, 4a, and 4j, represent promising multitarget leads for cholinergic and hCA-linked disorders. © 2026 Informa UK Limited, trading as Taylor & Francis Group.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Türkeş, Cüneyt | |
| dc.contributor.author | Yapar, Gönül | |
| dc.contributor.author | Duran, Hatice Esra | |
| dc.contributor.author | Lolak, Nebih | |
| dc.contributor.author | Akocak, Suleyman | |
| dc.date.accessioned | 2026-10-18T20:25:49.805491179Z | |
| dc.date.available | 2026-10-18T20:25:49.805491179Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Aims: To develop isovanillin-based bis-hydrazones as multitarget inhibitors of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and human carbonic anhydrase I/II (hCA I/II). Materials & methods: Twelve bis-hydrazones (4a–4l) were synthesized in two steps and evaluated by spectrophotometric enzyme assays, Lineweaver–Burk kinetics, molecular docking, MM-GBSA, molecular dynamics simulations, and in silico ADME/Tox profiling. Results: All compounds showed nanomolar inhibition. Compound 4d was the most potent AChE/BChE inhibitor (KI = 10.46 and 3.56 nM), while 4a and 4j led the hCA I/II panel (KI = 3.46 and 16.12 nM). Docking, MM-GBSA, and molecular dynamics supported dual-site cholinesterase engagement and non-zinc, peripherally anchored hCA inhibition. Conclusions: Isovanillin-based bis-hydrazones, particularly 4d, 4a, and 4j, represent promising multitarget leads for cholinergic and hCA-linked disorders. © 2026 Informa UK Limited, trading as Taylor & Francis Group. | |
| dc.description.sponsorship | This manuscript was partially funded by the Research Fund of Istanbul Technical University [grant number 33467]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Also, the authors acknowledge Cresset (Litlington, UK) for generously providing the Flare computer-aided drug design software suite, which was used to perform the molecular dynamics simulations and associated analyses presented in this study. | |
| dc.identifier.doi | 10.1080/17568919.2026.2617608 | |
| dc.identifier.eissn | 1756-8927 | |
| dc.identifier.endpage | 253 | |
| dc.identifier.issn | 1756-8919 | |
| dc.identifier.issue | 3 | |
| dc.identifier.pmcid | PMC12928624 | |
| dc.identifier.pmid | 41548080 | |
| dc.identifier.scopus | 2-s2.0-105027855565 | |
| dc.identifier.startpage | 237 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10656 | |
| dc.identifier.volume | 18 | |
| dc.identifier.wos | WOS:001664947500001 | |
| dc.language.iso | en | |
| dc.publisher | Taylor and Francis Ltd. | |
| dc.relation.ispartof | Future Medicinal Chemistry | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | ADMET profiling | |
| dc.subject | bis-hydrazone derivatives | |
| dc.subject | carbonic anhydrase inhibition | |
| dc.subject | cholinesterase inhibition | |
| dc.subject | Isovanillin | |
| dc.subject | molecular docking | |
| dc.subject | molecular dynamics | |
| dc.subject | Acetylcholinesterase | |
| dc.subject | Benzaldehydes | |
| dc.subject | Butyrylcholinesterase | |
| dc.subject | Carbonic Anhydrase I | |
| dc.subject | Carbonic Anhydrase II | |
| dc.subject | Carbonic Anhydrase Inhibitors | |
| dc.subject | Cholinesterase Inhibitors | |
| dc.subject | Humans | |
| dc.subject | Hydrazones | |
| dc.subject | Molecular Docking Simulation | |
| dc.subject | Molecular Dynamics Simulation | |
| dc.subject | Molecular Structure | |
| dc.subject | Structure-Activity Relationship | |
| dc.subject | acetazolamide | |
| dc.subject | bishydrazone derivative | |
| dc.subject | carbonate dehydratase I | |
| dc.subject | carbonate dehydratase II | |
| dc.subject | cholinesterase | |
| dc.subject | hydrazone derivative | |
| dc.subject | tacrine | |
| dc.subject | unclassified drug | |
| dc.subject | benzaldehyde derivative | |
| dc.subject | carbonate dehydratase inhibitor | |
| dc.title | Isovanillin-derived bis-hydrazones as dual cholinesterase and carbonic anhydrase inhibitors: synthesis, enzymatic profiling, and computational insights from molecular docking and dynamics | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 10 | |
| rdl.citation.wos | 11 | |
| rdl.department | Department of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, Erzincan, Türkiye. | |
| rdl.oa.status | green | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
